Dr Testa first began working on AKT in the mid1980s, when he mapped the chromosomal location of the human AKT1 gene by in situ hybridization technique. Upon moving to Fox Chase Cancer Center, he and Dr Philip Tsichlis initiated a collaboration that resulted in the discovery that the retroviral oncogene v-akt harbors Gag sequences fused to a protein kinase C-related serine/threonine kinase of cellular origin. They also reported that the predicted protein has a structural motif (now known to include a PH domain) implicated in cell signaling. Dr Testa's group is perhaps best known for its isolation and characterization of mammalian AKT2 cDNAs and the first demonstration of recurrent amplification and overexpression of AKT2 in human cancers. His group also provided early evidence that targeting of AKT2, using antisense RNA, could selectively block growth of pancreatic cancer cells overexpressing this gene, but had no effect on pancreatic carcinoma cells lacking overexpression of AKT2. Subsequent work by many groups, including his own, has shown that activation of the AKT pathway by various mechanisms is among the most common molecular alterations in human cancer, and many investigators are now attempting to exploit therapeutically cancer cells' dependence on AKT signaling by screening for selective inhibitors of the AKT pathway.
In addition to his work on AKT, Dr Testa has had a longstanding interest in profiling molecular genetic alterations in human malignant mesothelioma, a type of cancer linked to asbestos exposure. He has identified frequent mutations of several different tumor suppressor genes, including NF2, in mesothelioma. His group has also shown that the product of the NF2 gene, merlin, plays a role in p21-activated kinase signaling and in regulating the expression of cyclin D1. While at the Fox Chase Cancer Center, Dr Tsichlis and Dr Testa initiated a collaboration that resulted in the cloning and characterization of v-akt and its cellular homolog c-akt. Subsequent work in Dr Tsichlis's laboratory revealed that Akt is activated by external signals via PI3K-dependent mechanisms.
In addition to his work on Akt, Dr Tsichlis has a longstanding interest in genetic alterations associated with cancer. During his postdoctoral work in Dr Coffin's laboratory, he showed that the major determinant of the oncogenic potential of animal retroviruses resides in the proviral LTR. Based on this work, Tsichlis and Coffin proposed the model of promoter insertion for Oncogenesis. Subsequently, Dr Tsichlis employed insertional mutagenesis as a tool to identify genes that are involved in tumor induction and progression and he used some of these genes as probes to explore function from the molecular to the animal level. Genes identified and exploited in the Tsichlis lab to date include, in addition to Akt, Tpl2, Gfi-1 and Gfi-1B. His work highlights the value of genetic studies in animal models for understanding the molecular basis of cancer and other diseases in humans.
